Cargando…
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
There is a need for therapeutic approaches to prevent and mitigate the effects of Coronavirus Disease (2019) (COVID-19). The histone deacetylase (HDAC) inhibitor valproic acid, which has been available for the therapy of epilepsy for many years, is a drug that could be repurposed for patients with s...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923868/ https://www.ncbi.nlm.nih.gov/pubmed/33667455 http://dx.doi.org/10.1016/j.ejphar.2021.173988 |